Jump to: Authorized Access | Attribution | Authorized Requests

Study Description
The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131). The goal of this study is to identify the molecular basis for response and resistance to targeted therapies that are matched to specific genomic alterations found in their cancers. Arm P is one of the treatment sub-protocols within the NCI-MATCH Clinical Trial (EAY131) where patients with PTEN loss by IHC are treated with the drug GSK2636771. This subprotocol is one of the treatment arms included in the CS-MATCH-0007 protocol and will provide specimens for the program including DNA from tumor tissue and whole blood.
Authorized Access
Publicly Available Data
  Link to other NCBI resources related to this study
Study Inclusion/Exclusion Criteria

Patients must fulfill all applicable eligibility criteria outlined in the MATCH Master Protocol.

Selected Publications
Diseases/Traits Related to Study (MeSH terms)
Links to Related Genes
Authorized Data Access Requests
See articles in PMC citing this study accession
Study Attribution
  • Principal Investigator
    • Lyndsay Harris, MD. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Funding Source
    • Division of Cancer Treatment and Diagnosis. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.